U.S. Health Department Names Permanent Heads for Key FDA Centers

What's Happening

The U.S. Department of Health and Human Services has made several important leadership appointments at the Food and Drug Administration (FDA), turning acting leaders at two of the agency's most important regulatory centers into permanent directors. (Reuters)

Michael Davis has been named permanent director of the Center for Drug Evaluation and Research (CDER), while Karim Mikhail will permanently lead the Center for Biologics Evaluation and Research (CBER). Both had previously been serving in acting roles. (Reuters)

The FDA also named Jared Seehafer as its first deputy commissioner for technology and artificial intelligence and formally appointed Bret Koplow as director of the Center for Tobacco Products. (Reuters)

The appointments come at a particularly important moment for the FDA. The agency has lost more than 3,000 employees over the past year, including senior division leaders, following major workforce cuts across HHS. (Reuters)

Michael Davis Will Permanently Lead the Drug Review Center

CDER oversees medicines

Davis has been appointed director of the Center for Drug Evaluation and Research, the FDA division responsible for evaluating and regulating drugs.

He had served as CDER's deputy director for about a year before becoming acting director in May. The new appointment gives him permanent responsibility for one of the agency's most important divisions. (Reuters)

CDER's work directly affects pharmaceutical companies because it oversees the regulatory pathway for medicines, including evaluations of new drugs and decisions that can determine whether products reach the U.S. market.

Why permanent leadership matters

Having a permanent director can provide more stability than relying on a succession of acting officials.

For drugmakers, a stable leadership structure can make it easier to understand how the agency is approaching issues such as drug approvals, clinical evidence, manufacturing and post-market regulation.

The timing is particularly significant because the FDA has been dealing with staff losses and internal disruption.

Karim Mikhail Will Lead the Biologics Center

CBER oversees vaccines and other biologics

Mikhail has been named permanent director of the Center for Biologics Evaluation and Research.

CBER regulates vaccines and other biological products, making its leadership particularly important for biotechnology companies and manufacturers developing complex therapies. (Reuters)

Mikhail had previously worked at the FDA as an adviser before becoming acting director of CBER. (Reuters)

His permanent appointment gives the biologics center a defined leader as the FDA navigates a rapidly changing biotechnology environment.

Biologics are becoming increasingly important

The biologics sector includes many of the healthcare industry's most advanced therapies, including vaccines and other complex biological treatments.

As pharmaceutical development increasingly shifts toward biologics and other advanced therapies, regulatory decisions at CBER can have significant consequences for companies investing in these markets.

FDA Creates Its First Technology and AI Deputy Commissioner Role

Jared Seehafer gets a new mandate

One of the most notable appointments is the creation of a new senior technology position.

Jared Seehafer has been appointed as the FDA's first deputy commissioner for technology and artificial intelligence. (Reuters)

The position reflects the growing role of technology and AI across healthcare and within the FDA itself.

The agency increasingly needs to deal with technologies ranging from AI-enabled medical products and software to data systems used in regulatory and healthcare processes.

AI is becoming part of the FDA's operating environment

The creation of a dedicated senior AI and technology role suggests that digital technology is no longer being treated as a side issue within the agency.

It indicates that the FDA expects technology and AI to become more integrated into its work, including potentially the way healthcare products are evaluated, monitored and regulated.

According to Reuters, the government plans to have two FDA deputy commissioners, with one focused on technology, including healthcare and AI, and another overseeing drugs. (Reuters)

Bret Koplow Will Lead the Center for Tobacco Products

The FDA also formally appointed Bret Koplow as director of its Center for Tobacco Products.

Koplow had previously been serving as the center's acting head. (Reuters)

The tobacco center oversees a highly controversial area of FDA regulation, covering tobacco and nicotine products and the companies that manufacture them.

Its decisions can affect products including cigarettes, vaping products and nicotine pouches.

The appointment therefore matters not only to public-health organizations but also to a large regulated consumer-product industry.

The Appointments Follow a Major Period of FDA Disruption

The agency has lost thousands of workers

The leadership changes come after a period of considerable upheaval at the FDA and the broader Department of Health and Human Services.

The FDA has lost more than 3,000 staff members over the past year, including division heads and other senior personnel. (Reuters)

The workforce losses followed major reductions initiated by Health Secretary Robert F. Kennedy Jr.

Reuters reported that the agency has faced declining morale and increasing pressure to rebuild confidence among both industry and public-health groups. (Reuters)

Leadership stability is now a major issue

The FDA's regulatory role requires deep scientific expertise and institutional knowledge.

Losing large numbers of experienced employees can make it harder for an agency to maintain continuity and process complex applications efficiently.

The appointment of permanent center directors is therefore part of a broader effort to rebuild a more stable leadership structure.

Heidi Overton Is Set to Lead the FDA

The appointments come shortly after President Donald Trump named White House policy aide Heidi Overton to lead the FDA.

Overton was selected in August to steer the agency as it deals with staff departures, low morale and disputes surrounding issues such as vaccines, the abortion pill and drug approvals. (Reuters)

The combination of a new FDA leader and permanent heads for major centers gives the agency a more defined leadership structure than it had during the period of acting appointments.

Why the Drug and Biologics Centers Matter So Much

The two centers receiving permanent directors are at the heart of the FDA's regulatory mission.

CDER affects the pharmaceutical pipeline

CDER decisions can influence whether new medicines are approved, how they are labeled and how drug safety is monitored.

Pharmaceutical companies therefore pay close attention to the center's leadership and regulatory priorities.

CBER affects vaccines and advanced biologics

CBER plays a similar role for vaccines and other biologic products.

Its decisions can influence development timelines, clinical requirements and commercialization opportunities for biotechnology companies.

Together, the two centers oversee a large portion of the products that drive the modern U.S. healthcare market.

Technology and AI Adds a New Regulatory Dimension

The new technology and AI position also signals that the FDA is preparing for a healthcare environment in which software and artificial intelligence increasingly overlap with traditional medical products.

AI can be used in clinical decision support, diagnostics, drug development, medical devices and healthcare operations.

That creates new regulatory questions around evidence, safety, model performance, transparency and ongoing monitoring.

Creating a dedicated leadership position suggests the agency expects those issues to become increasingly central.

The Tobacco Appointment Comes Amid Broader Nicotine Policy Changes

The appointment of Koplow is particularly relevant because the FDA has recently been under pressure to change how it handles newer nicotine products.

The agency's tobacco center has faced competing demands from the tobacco industry, which wants faster product decisions, and public-health groups, which want strong evidence that nicotine products do not increase addiction and youth use.

Permanent leadership at the center could therefore have a significant effect on the direction of future tobacco regulation.

Industry Confidence Is an Important Concern

Drugmakers need predictable regulation

The FDA's role is not simply to approve products.

For pharmaceutical and biotechnology companies, the agency is also a central source of regulatory predictability.

Companies invest billions of dollars based on assumptions about how clinical programs will be evaluated, how long reviews will take and what evidence regulators will require.

When an agency loses experienced staff and senior leaders, uncertainty can increase.

The latest appointments may help reduce that uncertainty by giving major regulatory centers permanent leadership.

Public-Health Groups Are Watching Too

The FDA's decisions also affect patients and public-health organizations.

Permanent leadership could shape approaches to vaccination, drug safety, biologic regulation and tobacco control.

That means rebuilding confidence is important on both sides of the healthcare system.

Industry needs confidence that the FDA can operate consistently and efficiently.

Public-health organizations need confidence that regulatory decisions are based on appropriate scientific evidence and adequately protect patients.

Why This Matters

These appointments are important because they address one of the FDA's biggest challenges right now: institutional stability.

The FDA is responsible for regulating medicines, vaccines, biologics and tobacco products, but it has been operating through a period of major staff losses and leadership changes.

Installing permanent leaders at CDER and CBER gives the agency greater continuity in two of its most important regulatory functions. (Reuters)

At the same time, creating a senior AI and technology position shows that the FDA is preparing for a healthcare industry increasingly shaped by digital technologies.

The appointments therefore represent both stabilization of the existing regulatory system and preparation for a more technology-driven healthcare market.

Looking Ahead

The next challenge for the FDA will be turning these personnel changes into greater operational stability.

Permanent directors can provide clearer accountability, but the agency will still need to address the loss of thousands of employees and rebuild scientific and regulatory capacity. (Reuters)

For the pharmaceutical and biotech industries, the important question will be whether the new leadership produces more predictable review processes, clearer regulatory expectations and stronger engagement with companies.

The new technology and AI leadership role will also be closely watched as the agency determines how AI should be incorporated into its own operations and how emerging healthcare technologies should be regulated.

Key Takeaways

• HHS has appointed Michael Davis as permanent director of the FDA's Center for Drug Evaluation and Research.
• Karim Mikhail has been named permanent director of the Center for Biologics Evaluation and Research. (Reuters)
• Both had previously served in acting leadership positions.
• Jared Seehafer has become the FDA's first deputy commissioner for technology and artificial intelligence. (Reuters)
• Bret Koplow has been named director of the Center for Tobacco Products.
• The FDA has lost more than 3,000 employees over the past year, including senior leaders. (Reuters)
• President Trump previously selected Heidi Overton to lead the FDA.
• The new leadership structure is intended to bring greater stability to the agency after a period of major workforce disruption.
• CDER is responsible for regulating medicines, while CBER oversees vaccines and other biologics.
• The new AI and technology role signals growing recognition of AI as a major part of healthcare regulation and operations.
• The leadership changes could influence regulatory predictability for pharmaceutical, biotech and healthcare companies.

What This Means for Healthcare Marketers

For healthcare marketers, these appointments are important because regulatory leadership can change the signals coming from the market long before a specific regulation changes.

Permanent leadership at CDER and CBER can influence how companies think about drug approvals, clinical evidence, biologics and launch timelines. The new AI leadership position creates another area to watch as technology becomes more deeply integrated into healthcare regulation.

The key market signal is who is now responsible for major regulatory decisions. Leadership changes at agencies such as the FDA can affect product launches, competitive timing, compliance requirements and the information healthcare companies need to make commercial decisions.